Literature DB >> 12044407

Drug resistance and influenza pandemics.

Nikolaos I Stilianakis, Alan S Perelson, Frederick G Hayden.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12044407     DOI： 10.1016/S0140-6736(02)08691-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.

Authors:  Hui-Ling Yen; Louise M Herlocher; Erich Hoffmann; Mikhail N Matrosovich; Arnold S Monto; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 2.  Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses.

Authors:  Elena A Govorkova
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

3.  Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.

Authors:  Hui-Ling Yen; Natalia A Ilyushina; Rachelle Salomon; Erich Hoffmann; Robert G Webster; Elena A Govorkova
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

Review 4.  Therapeutics against influenza.

Authors:  Elena A Govorkova; Jonathan A McCullers
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.